Chondrosarcoma - Pipeline Review, H1 2016

Description: Chondrosarcoma - Pipeline Review, H1 2016

Summary

‘Chondrosarcoma - Pipeline Review, H1 2016’, provides an overview of the Chondrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma
- The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chondrosarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Chondrosarcoma Overview
Therapeutics Development
Pipeline Products for Chondrosarcoma - Overview
Pipeline Products for Chondrosarcoma - Comparative Analysis
Chondrosarcoma - Therapeutics under Development by Companies
Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes
Chondrosarcoma - Pipeline Products Glance
Clinical Stage Products
Chondrosarcoma - Products under Development by Companies
Chondrosarcoma - Products under Investigation by Universities/Institutes
Chondrosarcoma - Companies Involved in Therapeutics Development
Agios Pharmaceuticals, Inc.
Celgene Corporation
CytRx Corporation
EpiZyme, Inc.
Horizon Pharma Plc
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
Chondrosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles

AG-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress

CC-90007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

interferon gamma-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress

pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress

pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress

selinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tazemetostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chondrosarcoma - Recent Pipeline Updates
Chondrosarcoma - Dormant Projects
Chondrosarcoma - Discontinued Products
Chondrosarcoma - Product Development Milestones
Featured News & Press Releases
May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Chondrosarcoma, H1 2016
Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Chondrosarcoma - Pipeline by Agios Pharmaceuticals, Inc., H1 2016
Chondrosarcoma - Pipeline by Celgene Corporation, H1 2016
Chondrosarcoma - Pipeline by CytRx Corporation, H1 2016
Chondrosarcoma - Pipeline by EpiZyme, Inc., H1 2016
Chondrosarcoma - Pipeline by Horizon Pharma Plc, H1 2016
Chondrosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Chondrosarcoma - Pipeline by Merck & Co., Inc., H1 2016
Chondrosarcoma - Pipeline by Novartis AG, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Chondrosarcoma Therapeutics - Recent Pipeline Updates, H1 2016
Chondrosarcoma - Dormant Projects, H1 2016
Chondrosarcoma - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Chondrosarcoma, H1 2016
Number of Products under Development for Chondrosarcoma - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3753827/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chondrosarcoma - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753827/
Office Code: SCD2LP8O

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>☐</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>☐</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World